Scott Power

Healthcare update - Monash ($MVF), Virtus ($VRT) and 3 emerging healthcare names: ow.ly/NpUUw #ASX #ausbiz

My interview with Michael Kavanagh, CEO and President of Nanosonics ($NAN): ow.ly/JHNln #ASX #ausbiz

I'll be posting video updates on the healthcare sector when time permits - here is today's edition: ow.ly/HNo7p #asx

Back from annual leave and feeling refreshed. I'll be updating our healthcare stocks milestone table in the weeks ahead. #ASX

Morgans Blog: Snr Analyst Scott Power on the major milestone achievement for Impedimed ($IPD) ow.ly/DHHbc #ASX #ausbiz

Impedimed ($IPD) share price up in a soft market - often a strong sign. Reimbursement newsflow 1st wk Nov. SP target A$0.72 #ASX #ausbiz

Admedus ($AHZ) - a high conviction call. Manufacturing plant opens today. Outlook for CardioCel is exciting: ow.ly/AlrQD #ASX

Volumes and share price for Impedimed ($IPD) are up and SP looks to be going higher. Federal registry announcement expected shortly.

Acrux ($ACR) a great run on Friday (+30%) - has run through our price target and we suggest taking profits. #ASX #ausbiz #markets

Innate Therapeutics ($IIL) is expected to start its MS trial in Aus in August. Key milestone - buy at A$0.19 for a run to mid 20s #ASX

Acrux ($ACR) update - Eli Lilly posts a solid quarterly result for Axiron. The market should like it and traders can take some profit. #ASX

I'm back from the Bioshares conference. A highlight was Impedimed ($IPD). Upgraded reimbursement code is the key - expect before end of Oct.

Snr Analyst Scott Power with his 3 companies to watch from the Bioshares Biotech Summit: ow.ly/znfHK #ASX #ausbiz